Bystolic(TM), A Novel Beta Blocker, Is Now Approved By The FDA For The Treatment Of Hypertension

Forest Laboratories, Inc. (NYSE: FRX) and Mylan Inc. (NYSE: MYL) announced that the novel beta blocker Bystolic(TM) (nebivolol) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension. Bystolic is a once daily medication that can be used alone or in combination with other hypertension treatments. Hypertension affects approximately 72 million adults in the U.S. [click link for full article]

More: continued here

Filed under: Hypertension on December 20th, 2007